Functional Concept – Page 69

SEC Staff Recommends Enforcement Action Against Allarity Over Potential Federal Securities Laws Violations

1 year ago talkbio0Tagged Allarity, Clinical action, Dovitinib, enforcement, federal, Rules of conduct, seconds, stenoparib, United States Food and Drug Administration, Violations

Allarity Therapeutics, SEC, Enforcement Action, Federal Securities Laws, Violations, Wells Notice, FDA, Dovitinib, Stenoparib

Eli Lilly, Novo Nordisk Shares Fall as their weight-Loss drugs face competition

1 year ago talkbio0Tagged CT-996, Eli, Eli Lilly, Glucagon-Like Peptide 1, Nordisk, Obesity, Pharmaceutical competition, Roche, Stock market, Wegovy, weight-loss drug market

, Eli Lilly, Novo Nordisk, Roche, Obesity drugs, Weight-loss drug market, Stock market, Pharmaceutical competition, GLP-1 therapy, CT-996, Zepbound, Wegovy,

George Church’s GRObio Secures $60 Million to Advance Gout Treatment into Clinical Trials

1 year ago talkbio0Tagged biotech, Clinical Trials, George Church, Gout, GRObio

GRObio, George Church, Gout Treatment, Clinical Trials, Biotech Funding

Agenus Faces Uphill Battle After FDA Rejects Accelerated Approval for Cancer Drug Combo

1 year ago talkbio0Tagged Accelerated, Agenus, Antineoplastic Agents, Approved, BOT, BOT/BAL, Colorectal Carcinoma, stock selloff, United States Food and Drug Administration

Agenus, FDA, Cancer Drug Combo, BOT/BAL, Colorectal Cancer, Accelerated Approval, Stock Selloff

FDA Discourages Accelerated Approval for Agenus’ Colorectal Cancer Combination, Prompting Partnership Search

1 year ago talkbio0Tagged Accelerated, Agenus, Approved, balstilimab, Botensilimab, Colorectal Carcinoma, Combined, Immunotherapy, Partnership, Phase 3 Clinical Trials, United States Food and Drug Administration

Agenus, FDA, Accelerated Approval, Colorectal Cancer, Botensilimab, Balstilimab, Immunotherapy Combination, Phase III Trial, Partnership

Orexo’s Opioid Overdose Nasal Spray Fails FDA Review for Second Time

1 year ago talkbio0Tagged Drug Overdose, Homo sapiens, naloxone, Nasal Spray, Opioids, Orexo, OX124, Technical Data, Techniques, United States Food and Drug Administration

Orexo, OX124, FDA, Nasal Spray, Opioid Overdose, Naloxone, Human Factors Study, Technical Data

Bayer’s NUBEQA Shows Promise in Prostate Cancer Treatment, Expanding Indications

1 year ago talkbio0Tagged ARAMIS, ARASENS, Bayer, Clinical Trials, Corporation, darolutamide, Hormone Responsive, Malignant neoplasm of prostate, Metastatic to, non-metastatic castration-resistant prostate cancer, Nubeqa, Orion

NUBEQA, darolutamide, prostate cancer, metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, ARASENS trial, ARAMIS trial, Bayer, Orion Corporation